Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, dated August 20, 2024, reports a specific transaction in the company's own shares. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS).
Key Financial Metrics and Transaction Details
The filing details a share buyback transaction executed under the programme announced on August 1, 2024. The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the period.
| Metric | Value |
|---|---|
| Date of Purchase | August 20, 2024 |
| Number of Shares Purchased | 651,294 |
| Highest Price Paid (p) | 372.60 |
| Lowest Price Paid (p) | 370.30 |
| Volume Weighted Average Price (p) | 371.73 |
| Post-Transaction Registered Share Capital | 9,127,304,752 ordinary shares |
Material Changes
The primary material change reported is the reduction of the company's registered share capital following the purchase and cancellation of 651,294 ordinary shares. No other material changes to financial performance or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
This filing does not contain updated financial guidance, management commentary on future outlook, or new risk factors. It serves strictly as a regulatory notification of the share repurchase activity in compliance with the Market Abuse Regulation (Article 5(1)(b)).
Key Facts for Investor Verification
- Verify the total number of shares repurchased to date under the August 1, 2024 Buyback Programme.
- Confirm the remaining authorized buyback limit and the programme's end date.
- Review the full trade breakdown available via the London Stock Exchange link provided in the filing for granular execution data.
- Check subsequent filings for the impact of this buyback on earnings per share (EPS) and total equity.